Everything below concerns nuclear receptor. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-07. Numbers and descriptions here follow the published literature rather than marketing material.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
== Signs and symptoms == Signs and symptoms of Huntington's disease most commonly become noticeable between the ages of 30 and 50 years, but they can begin at any age and present as a triad of motor, cognitive, and psychiatric symptoms. When developed in an early stage, it is known as juvenile Huntington's disease. In 50% of cases, the psychiatric symptoms appear first. These can precede the motor symptoms by many years. Disease progression is often described in early stages, middle stages and late stages with an earlier prodromal phase. In the early stages, subtle personality changes, problems in cognition and physical skills, irritability and mood swings occur, all of which may go unnoticed. Almost everyone with HD eventually exhibits similar physical symptoms, but the onset, progression, and extent of cognitive and behavioral symptoms vary significantly between individuals. The most characteristic initial physical symptoms are jerky, random and uncontrollable movements called chorea. Many people are not aware of their involuntary movements, or impeded by them. Chorea may be initially exhibited as general restlessness, small unintentionally initiated or uncompleted motions, lack of coordination, or slowed saccadic eye movements. These minor motor abnormalities usually precede more obvious signs of motor dysfunction by at least three years. The clear appearance of symptoms such as rigidity, writhing motions, or abnormal posturing appear as the disorder progresses. These are signs that the system in the brain that is responsible for movement has been affected.
Enamel is the hardest substance in the human body and contains the highest percentage of minerals, 96%, with water and organic material composing the rest. The primary mineral is hydroxyapatite, which is a crystalline calcium phosphate. Enamel is formed on the tooth while the tooth is developing within the gum, before it erupts into the mouth. Once fully formed, it does not contain blood vessels or nerves. Remineralisation of teeth can repair damage to the tooth to a certain degree but damage beyond that cannot be repaired by the body. The maintenance and repair of human tooth enamel is one of the primary concerns of dentistry. In humans, enamel varies in thickness over the surface of the tooth, often thickest at the cusp, up to 2.5 mm, and thinnest at its border with the cementum at the cementoenamel junction. The normal color of enamel varies from light yellow to grayish (bluish) white. At the edges of teeth where there is no dentin underlying the enamel, the color sometimes has a slightly blue tone. Since enamel is semitranslucent, the color of dentin and any material underneath the enamel strongly affects the appearance of a tooth. The enamel on primary teeth has a more opaque crystalline form and thus appears whiter than on permanent teeth. The large amount of mineral in enamel accounts not only for its strength but also for its brittleness. Tooth enamel ranks 5 on Mohs hardness scale and has a Young's modulus of 83 GPa. Dentin, less mineralized and less brittle, 3–4 in hardness, compensates for enamel and is necessary as a support.
=== (2) Separation and quantification methods === Separation methods are the first step to decomplexify the venom sample, with a common method being reverse‐phase high performance liquid chromatography (RP-HPLC). This method can be applied broadly to nearly all venoms as a crude fractionation method and to detect the peptide bonds found. A less common techniques like 1D/2D gel electrophoresis can also be used in cases of venoms containing heavy, complex peptides (Preferable >10KDa). This means in additions to RP-HPLC, Gel electrophoresis can help identify large molecules (such as enzymes) and to help refine venom prior to further analytical methods. Next, N-terminal sequencing is used to find the amino acid order of the fractionated proteins/peptides starting with the N-terminal end. Furthermore, SDS‐PAGE (Sodium dodecyl sulfate-polyacrylamide gel electrophoresis) can be performed on the isolated proteins from the RP-HPLC to identify proteins of interest before moving on to the identification stage.
Sources: en.wikipedia.org
=== Genetic modification === A type of salmon called the AquAdvantage salmon has been genetically modified for faster growth, although it has not been approved for commercial use, due to controversy. The altered salmon incorporates a growth hormone from a Chinook salmon that allows it to reach full size in 16–28 months, instead of the normal 36 months for Atlantic salmon, and while consuming 25 percent less feed. The U.S. Food and Drug Administration reviewed the AquAdvantage salmon in a draft environmental assessment and determined that it "would not have a significant impact (FONSI) on the U.S. environment."
While Kutuzov had recognized the political need to give battle, he also recognized that Barclay de Tolly's strategies had proven effective, and that the Grande Armée was bleeding personnel and supplies more and more severely with every step they took deeper into Russia. Napoleon's logistical difficulties meant that French casualties simply could not be replaced, whereas the Russian army could reinforce itself far more readily. Napoleon I entered Moscow on 14 September, after the Russian Army had retreated yet again. By then, the Russians had largely evacuated the city and released criminals from the prisons to inconvenience the French; the governor, Count Fyodor Rostopchin, ordered the city to be burnt. Alexander I refused to capitulate, and the peace talks attempted by Napoleon failed. Rather than withdraw further east, the Russian army withdrew south, rebuilding its strength and preparing to interfere with a French withdrawal. In October, with no sign of clear victory in sight, Napoleon began the disastrous Great Retreat from Moscow.
=== MeSH D12.644.400 – neuropeptides === MeSH D12.644.400.070 – angiotensins MeSH D12.644.400.070.075 – angiotensin i MeSH D12.644.400.070.078 – angiotensin ii MeSH D12.644.400.070.080 – angiotensin iii MeSH D12.644.400.085 – bombesin MeSH D12.644.400.090 – bradykinin MeSH D12.644.400.095 – calcitonin MeSH D12.644.400.097 – calcitonin gene-related peptide MeSH D12.644.400.100 – carnosine MeSH D12.644.400.105 – cholecystokinin MeSH D12.644.400.120 – corticotropin MeSH D12.644.400.125 – corticotropin-releasing hormone MeSH D12.644.400.200 – delta sleep-inducing peptide MeSH D12.644.400.235 – fmrfamide MeSH D12.644.400.250 – galanin MeSH D12.644.400.275 – galanin-like peptide MeSH D12.644.400.300 – gastric inhibitory polypeptide MeSH D12.644.400.315 – gastrin-releasing peptide MeSH D12.644.400.320 – gastrins MeSH D12.644.400.340 – glucagon precursors MeSH D12.644.400.340.500 – glucagon MeSH D12.644.400.350 – gonadorelin MeSH D12.644.400.450 – motilin MeSH D12.644.400.460 – melanocyte-stimulating hormones MeSH D12.644.400.460.050 – alpha-msh MeSH D12.644.400.460.075 – beta-msh MeSH D12.644.400.460.115 – gamma-msh MeSH D12.644.400.465 – msh release-inhibiting hormone MeSH D12.644.400.470 – msh-releasing hormone MeSH D12.644.400.500 – neuropeptide y MeSH D12.644.400.525 – neurophysins MeSH D12.644.400.550 – neurotensin MeSH D12.644.400.575 – opioid peptides MeSH D12.644.400.575.180 – dynorphins MeSH D12.644.400.575.241 – endorphins MeSH D12.644.400.575.241.030 – alpha-endorphin MeSH D12.644.400.575.241.080 – beta-endorphin MeSH D12.644.400.575.241.360 – gamma-endorphin MeSH D12.644.400.575.281 – enkephalins MeSH D12.644.400.575.281.075 – enkephalin, ala(2)-mephe(4)-gly(5)- MeSH D12.644.400.575.281.231 – enkephalin, leucine MeSH D12.644.400.575.281.381 – enkephalin, methionine MeSH D12.644.400.575.281.600 – enkephalin, d-penicillamine (2,5)- MeSH D12.644.400.600 – pancreatic polypeptide MeSH D12.644.400.610 – peptide phi MeSH D12.644.400.625 – pituitary adenylate cyclase-activating polypeptide MeSH D12.644.400.640 – pituitary hormone release inhibiting hormones MeSH D12.644.400.645 – pituitary hormone-releasing hormones MeSH D12.644.400.680 – prolactin release-inhibiting hormone MeSH D12.644.400.700 – prolactin-releasing hormone MeSH D12.644.400.702 – thyrotropin-releasing hormone MeSH D12.644.400.705 – secretin MeSH D12.644.400.720 – somatostatin MeSH D12.644.400.740 – somatotropin-releasing hormone MeSH D12.644.400.800 – tachykinins MeSH D12.644.400.800.354 – eledoisin MeSH D12.644.400.800.475 – kassinin MeSH D12.644.400.800.500 – neurokinin a MeSH D12.644.400.800.550 – neurokinin b MeSH D12.644.400.800.625 – physalaemin MeSH D12.644.400.800.750 – substance p MeSH D12.644.400.875 – vasoactive intestinal peptide MeSH D12.644.400.900 – vasopressins MeSH D12.644.400.900.050 – argipressin MeSH D12.644.400.900.400 – lypressin MeSH D12.644.400.900.700 – oxytocin MeSH D12.644.400.900.900 – vasotocin
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.